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Case report 
Chronic vulvar Paget’s disease: a 
therapeutic challenge with a review of 
the literature 
 
Bouhani Malek1, Zemni Ines1, Fertani Yasmine1, Bouzaiene Hatem1, Rahal Khaled1 
 1Department of oncologic surgery, Salah Azaiz Institute, Tunis Tunisia 
Abstract Vulvar Paget’s disease is an uncommon adenocarcinoma of the female genital tract, 
occuring more often in postmenopausal Caucasian women and accounting for 1-2% of all 
vulvar malignancies. A 39-year-old female patient was examined for the erythematous and 
pruritic vulvar lesion, with biopsy and histological examination revealing vulvar Paget’s 
disease. We did not diagnose any associated neoplasm. The patient underwent four 
surgical resections for relapsed disease, varying from local excision to extended excision, 
including radical vulvectomy, with esthetic coverage. The margins were involved. Due to 
the extended target volumes, radiotherapy was rejected and the patient underwent a local 
topical therapy with Imiquimod 5%. The patient was free of disease, with three years of 
regular follow-ups. This case was challenging due to the long recurrence of the disease for 
approximately 26 years and due to the therapeutics issues that occurred. 
Keywords  vulvar neoplasm, reconstructive surgical procedures, extramammary Paget’s disease, 
Imiquimod 
Highlights ✓ Vulvar Paget’s disease is a therapeutic challenge for physicians due to its chronicity and 
its high rate of recurrence. The management of local recurrence is associated with 
mutilating surgery.  
✓ Currently, new conservative approaches such as local cream use, laser therapy, and many 
other treatments are being adopted. Imiquimod 5% cream is an alternative for 
consideration in the case of invaded margins. 
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Introduction 
In 1876, Sir James Paget observed chronic eczematous 
disease on the skin of the nipple and areola that was 
associated with a breast intraductal carcinoma (1). This 
entity was defined as mammary Paget’s disease. Later, in 
1901, William Dubreuilh described vulvar Paget’s disease 
(VPD) (2). VPD is an uncommon adenocarcinoma of the 
female genital tract (3). It occurs more often in 
postmenopausal Caucasian women (3) and accounts for 1-
2% of all vulvar malignancies (3, 4).  
Given its chronicity, the disease is under-diagnosed, 
thus leading to a real therapeutic challenge for physicians. 
Surgery remains the treatment of choice; however, many 
new therapeutic approaches also seem appealing. We cite 
radiotherapy, topical therapy, laser therapy, photodynamic 
therapy, and radiotherapy as possibilities (5-10). Despite 
these varied therapies, VPD still has high relapse rates, 
ranging from 15 to 72% (5, 7, 8, 11). 
Case report 
In 1990, a 39-year-old Caucasian woman presented 
with an erythematous lesion on the left hemi vulva at 
another medical facility. She underwent local excision of 
the lesion and the histological report revealed VPD, but the 
limits and the invasion were not determined. She did not 
undergo adjuvant therapy, and her case was subsequently 
lost over time. Twenty-two years later (in 2012), she 
presented with a new though similar lesion in the same 
localization. The patient underwent mammography, 
coloscopy, gastric endoscopy, and cystoscopy, and all 
results were negative. She then underwent left 
hemivulvectomy. The final histological examination 
concluded VPD again, and the limits were free with a 2-
mm clearance.   
Three years later (in 2015), after the first relapse, she 
presented with an erythematous lesion on the right 
hemivulva and the perianal region. The inguinal areas were 
free of lymph nodes. The punch biopsy with histological 
examination confirmed the recurrence of VPD. She had a 
totalization of the vulvectomy with excision of the peri-
anal lesion and an advanced flap of the inner thigh. We 
performed a left iliac colostomy to improve the peri-anal 
scarring. The limits were not free, but the patient was lost 
again. One year later (in 2016), she was referred to our 
institute for an evolutive disease. The physical examination 
revealed multiple erythematous lesions located in mons 
veneris, in the flap and in the perianal region (Figures 1 and 
2). 
 
Figure 1. General overview showing multiple 
erythematous lesions located in mons veneris, in the 
flap and in the peri-anal region (red circles). 
 
Figure 2. Closeup overview of multiple 
erythematous lesions located in mons veneris, in the 
flap and in the peri-anal region (red arrows).  
We performed punch biopsies for each suspicious 
lesion, and the histological examination confirmed the 
VPD recurrence. She underwent a large excision and 
coverage by a V-Y flap of the inner thigh (Figures 3 and 
4). 
 
Figure 3. Large excision of the perineal areas, mons 
veneris and the flap.  
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Figure 4. Coverage by a V-Y flap of the inner thigh 
Frozen section examination pointed to free limits, but 
final histology exams showed involved margins. Due to the 
multiple recurrences of the disease and the involved 
margins, the patient was proposed for external beam 
therapy. But radiotherapy was rejected due to the extent of 
the target volumes. The multidisciplinary committee 
indicated a topical therapy with Imiquimod 5%. The 
patient underwent local therapy with imiquimod 5% twice 
a week for 6 months. At the time of this publication, the 
patient is 68 years old and she had no recurrence in the first 
36 months after treatment.  
Discussions 
Vulvar Paget’s disease remains underdiagnosed due to 
its rarity and its clinical presentation which mimics a 
benign lesion. Wilkinson and Brown proposed a 
classification that divided it into two entities: primary and 
secondary disease (12). Primary Paget’s disease is an 
intraepithelial adenocarcinoma that occurs in the 
appendages of the epidermis or the underlying skin. 
Secondary Paget’s disease is associated with underlying 
noncutaneous adenocarcinoma, most frequently anorectal 
adenocarcinoma, and urothelial carcinoma of the bladder 
or urethra, carcinoma of the cervix, ovaries, or 
endometrium (13). For this reason in our case, we did a full 
workup so as to avoid underdiagnosing an underlying 
adenocarcinoma.  
The VPD mechanism of spreading is still under debate. 
Mehta et al. supposed that a Pagetoid tumor spreads 
throughout the basal layers and the alteration of the tumor 
microenvironment is responsible for the progression of the 
disease (14).  
Throughout time, surgery has been the main treatment 
of VPD, but VPD extends beyond the clinical limits of the 
lesion. In fact, the spread of Paget’s cells may be difficult 
to recognize in a frozen section examination. This makes 
margin control hard to achieve. The preferred surgical 
method uses Mohs micrographic surgery to avoid false-
negative free margins in the results of the frozen section, 
as in our case (15). Surgery varies from local excision to 
radical vulvectomy, with a high risk of recurrence 
regardless of the margin status which then leads to 
increasingly mutilating surgery, and thus plastic 
reconstructive surgery is often needed to cover the tissue 
loss, as in our case. 
Because of the mutilating surgery, a variety of other 
therapeutic means have been attempted (8-10).  
Radiotherapy alone or associated with chemotherapy 
remains a treatment option for the relapsing disease (16, 
17). But the high morbidity of those treatments has 
stimulated the search for less invasive treatment options 
such as chemotherapy with intralesional interferon alfa-2b, 
bleomycin, laser ablation, photodynamic therapy, topical 
fluorouracil (5-Fu), and imiquimod 5% cream.  
The conservative treatment approach is promising 
because it conserves the vulvar anatomy and the sexual 
functions. Laser therapy was successfully used, but the 
major disadvantages are the high rate of recurrence and the 
significant pain level (18, 19).  
Imiquimod 5%—an  immune response modifier—is a 
known treatment for vulvar condyloma, actinic keratosis, 
or even basal cell carcinoma. The treatment also has a 
direct antitumor activity, being first described as a local 
treatment for VPD in 2003 by Wang et al. (20). A 
systematic review conducted by Dogan showed the 
efficacity of imiquimod as an alternative for VPD, with a 
complete remission rate of 71% (21). However, treatment 
protocols for imiquimod are not well codified. 
Applications are generally about 3 per week, although with 
widely variable durations. In our case, radiotherapy could 
not be performed due to the extent of the target volumes. 
Imiquimod 5% was applied twice a week for 28 weeks, 
with excellent results, confirming both the efficacy and 
safety of Imiquimod 5% cream in the treatment of VPD.  
Another promising treatment option of VPD is topical 
photodynamic therapy (PDT), with good outcomes 
reported by Rioli (22), although other reports have shown 
a high rate of recurrence (23). Target therapy still needs to 
be approved in the treatment of VPD when HER-2/neu is 
overexpressed. 
Conclusions 
The most challenging feature in the management of 
VPD is its recurrence because the patient has undergone 
increasingly mutilating surgery that leads, in some cases, 
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to an impossible challenge for the surgeon. Imiquimod 5% 
cream appears to be a viable alternative in such situations. 
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